ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceutical Chemicals

Biogen invests in neuroscience start-ups C4 and Skyhawk

by Lisa M. Jarvis
January 14, 2019 | APPEARED IN VOLUME 97, ISSUE 2

 

In a deal potentially worth $415 million, Biogen and C4 Therapeutics will jointly develop protein degraders for neurological conditions, including Alzheimer’s and Parkinson’s diseases. While conventional small-molecule drugs typically inhibit protein function, degraders force bad-behaving proteins to be tagged for the cellular trash bin. Separately, Biogen will work with Skyhawk Therapeutics to develop small molecules that modulate RNA splicing—the way that stretches of RNA are pieced together to form the code for building a protein. Skyhawk will get $74 million up front to develop treatments for neurological diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment